Abstract: O-derivatized alginic acid antigens capable of eliciting opsonizing antibodies in vivo are described. The O-derivatized antigens show enhanced antigenicity and immunogenicity relative to native, non-O-derivatized alginic acid antigens, particularly the MEP antigen of P. aeruginosa. Pharmaceutical compositions containing the O-derivatized antigens of the invention are also described. The invention also pertains to use of the compositions as vaccines, in immunodiagnostic assays, and in methods for producing monoclonal antibodies reactive against the antigen.Methods for forming O-derivatized alginic acid antigens of the invention are described. A non-O-derivatized starting material is reacted in a solvent with an alkyl anhydride derived from a fatty acid.

Abstract: The present invention relates to inulin derivatives of the general formula I ##STR1## in which R=--CH.sub.2 OH, --CHOH--(CH.sub.2).sub.m --CH.sub.3,m is an integer from 0 to 10,n is on average a number from 10 to 50,a and b is a number from 0 to 3, where a+b=3,G is a glucopyranose group andF is a fructofuranose group,to a process for their preparation and to their use.

Abstract: The present invention relates to compositions and methods for inhibiting or preventing growth of dental plaque on tissues within the human oral cavity comprising topical administration, to tissues of a human oral cavity, of a composition comprising a safe and effective amount of Actinomyces viscosus fimbriae.

Abstract: Compositions and methods for prevention of adhesion formation, whereby an effective amount of at least one compound selected from dipyridamole and analogs thereof is administered as active agent for a period of time sufficient to permit tissue repair. The active agent is preferably administered in conjunction with a delivery vehicle (e.g., microcapsules, microspheres, lipid-based systems, viscous instillates and absorbable mechanical barriers) useful for maintaining local concentrations of the compound at an effective level.

Abstract: There is disclosed a process for producing sucralose from sucralose-6-ester whereby the sucralose-6-ester is deacylated directly either prior to or after removal of the tertiary amide reaction vehicle from the neutralized chlorination reaction mixture, to produce an aqueous solution of sucralose plus salts and impurities, from which sucralose is recovered by extraction and is then preferably purified by crystallization.

Abstract: Described herein are preparations containing parathyroid hormone that has been stablized with an excipient and buffering agent. Preferred preparations incorporate human PTH(1-84), mannitol as excipient and citrate as buffering agent, and are incorporated in vials as a freeze-dried powder for reconstitution to treat osteoporosis.

Abstract: Dental products employing a ternary surfactant system of poloxamers, anionic polysaccharides, and nonionic cellulose ethers. This ternary surfactant system has greatly enhanced foaming power relative to poloxamers alone or to poloxamers plus anionic polysaccharides or to poloxamers plus nonionic cellulose ethers. The poloxamer-anionic polysaccharide-nonionic cellulose ether surfactant system has little or no taste, is nonirritating, and has excellent adhesion to tooth surfaces and oral mucosa. Inclusion of a mild abrasive plus one or more of xylitol, raw licorice, licorice extract, and glycyrrhizin and its derivatives enhances the clinical efficacy of the formulations by further reducing plaque buildup thus brightening teeth and reducing tooth decay and periodontal disease.The surfactant system can be used in a dentifrice paste or gel, powder, granules, disintegrable tablet, and a mouthwash, lozenge, and chewing gum.

Abstract: A polysaccharide substance having the following formula is provided: ##STR1## Also provided is a method of producing the polysaccharide substance in which an oligosaccharide having a degree of polymerization from 3 to 10 is chemically bonded to a silane agent at the reducing terminal of the resultant oligosaccharide, the oligosaccharide compound is then polymerized to an average degree of polymerization from 11 to 500 in the presence of an enzyme. Another method for producing the polysaccharide substance is provided in which an aldehyde group at the reducing terminal of an oligosaccharide having a degree of polymerization from 3 to 10 is oxidized with an oxidizing agent, and the saccharide chain of the oxidized product is polymerized to a degree of polymerization from 11 to 500 in the presence of an enzyme, followed by the addition of an acid. The polysaccharide substance has excellent solvent resistance and is useful as a separating agent for chromatography, especially for the separation of chiral compounds.

Abstract: A process for highly regioselective esterification and ester cleavage on unsaturated sugar compounds with the aid of lipases and esterases, and products which can be prepared by this process.Highly regioselective esterifications and ester cleavages can be carried out on unsaturated sugar compounds with the aid of lipases and esterases. Lipases from microorganisms or from the pancreas and liver of animals are preferably used.

Abstract: A topical composition comprising an amount of a carbonic anhydrase inhibitor and an amount of .beta.-cyclodextrin derivative effective in increasing the bioavailability of the carbonic anhydrase inhibitor when coadministered topically to the eye.

Abstract: The treatment of erectile dysfunctions in mammals, including humans, comprises administering to a host in need thereof an effective dose of linsidomine or a pharmacologically compatible salt thereof, alone or in combination with adenosine, vitamins, prostaglandins, calcium antagonists, .alpha.-receptor blockers and/or smooth muscle relaxants. Also disclosed is a disposable medicament pack containing in a sterile package a disposable syringe containing a dose unit of an erection-promoting active substance or of a combination of active substances, sterile swabs provided with disinfectants, and instructions for use.

Abstract: A method for reducing the number of contaminative live bacteria in xanthan gum which comprises the step of washing a mixture of 100 parts by weight of water-containing isopropanol having an isopropanol concentration of 50 to 100% by weight and 1 to 100 parts by weight of the xanthan gum under heating conditions.

Abstract: Disclosed is a semi-solid pharmaceutical agent containing a stabilized proteinaceous bioactive substance prepared by successively mixing an oligosaccharide and an aqueous solution of a proteinaceous bioactive substance, and kneading the resultant solids with an oil or fat base. The pharmaceutical handles with ease because it is readily administered to the body through percutaneous and permucosal route which are safer and less in pain administration routes than other conventional administrations.

Abstract: Guar gum which demonstrates greater than 75% light transmission at a wavelength of from about 500-600 nanometers when dispersed in water in the amount of 0.5 parts per 100 parts water and the process for producing such guar gum is disclosed.

Abstract: This invention is a process for comminuting a cellulose ether which comprises extruding a hydrated cellulose ether through a plurality of orifices, each orifice having a cross-sectional area of from about 7.5.times.10.sup.-9 m.sup.2 to about 1.times.10.sup.-6 m.sup.2, to form an elongated extrudate, and then cutting the elongated extrudate to desired length. The high density cellulose ether product is typically cold water dispersible, non-dusty, and free flowing.

Abstract: A pharmaceutical composition is disclosed which comprises a solution of an HIV protease inhibiting compound in a pharmaceutically acceptable organic solvent comprising a mixture of (1) (a) a solvent selected from propylene glycol and polyethylene glycol or (b) a solvent selected from polyoxyethyleneglycerol triricinoleate, polyethylene glycol 40 hydrogenated castor oil, fractionated coconut oil, polyoxyethylene (20) sorbitan monooleate and 2-(2-ethoxyethoxy)ethanol or (c) a mixture thereof and (2) ethanol or propylene glycol.

Abstract: A sustained-release pharmaceutical composition comprising a highly soluble pharmaceutical agent, such as selegiline, in a pharmaceutical carrier comprising a hydrophilic polymer dispersed in a hydrophobic matrix. A hydrophilic microenvironment is created in a hydrophobic matrix by incorporating hydrophilic polymers within a hydrophobic matrix. Optionally, a binder, preferably a polyhydroxylated compound, ca also be added.

Abstract: This invention relates to treatment of antibiotic associated diarrhea, including Clostridium difficile associated diarrhea (CDAD) and pseudomembranous colitis (PMC), using oligosaccharide compositions which bind C. difficile toxin A. More specifically, the invention concerns neutralization of C. difficile toxin A associated with CDAD.

Abstract: An external skin treatment composition containing (I) vitamin A (retinol) and (II) as a stabilizer, a chelating agent/a polysaccharide, an oil, polyethylene (propylene) glycol, a hydroxy carboxylate, a neutral amino acid salt, an oil-soluble antioxidant/EDTA/a benzophenone compound, an oil-soluble antioxidant/an acid/a benzophenone compound, an inclusion compound of cyclodextrin including an antioxidant and/or an ultraviolet absorber, butanediol and/or an oil-soluble antioxidant, a water-soluble benzophenone compound, a basic amino acid and the salt thereof, an acidic amino acid and the salt thereof, a polar oil, a water-swellable clay mineral.

Abstract: Compositions comprising (i) granules comprising a biologically active material in association with a weak base and partially coated with a delayed release material soluble in intestinal juice, (ii) an acidifying agent having a pH between 1.5 to 6, and (iii) a gel forming agent are described. There is also described a composition comprising an acidic gel having a pH between 1.5 to 6 and containing microgranules comprising a biologically active material in association with a weak base and partially coated with a delayed release material soluble in intestinal juice. The compositions may be used in the treatment of diseases associated with intestinal pathogens in animals. Where the biologically active material is a protease, receptor/adhesion sites in the intestines for pathogens may be proteolysed so as to prevent pathogen binding to intestinal surfaces.